Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Not yet recruiting
Kala Pharmaceuticals, Inc.
Phase 4
2021-12-01
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25%
ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year
after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long
been the mainstay for preventing and treating cornea transplant rejection although none are
specifically approved for this purpose. The rates of immunologic rejection episodes and
steroid-induced ocular hypertension will be compared with the respective rates observed in
earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and
fluorometholone 0.1% suspension after DMEK.
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Not yet recruiting
Price Vision Group
Phase 4
2021-12-01
The purpose of this study is to assess off-label use of loteprednol etabonate 0.25%
ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year
after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long
been the mainstay for preventing and treating cornea transplant rejection although none are
specifically approved for this purpose. The rates of immunologic rejection episodes and
steroid-induced ocular hypertension will be compared with the respective rates observed in
earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and
fluorometholone 0.1% suspension after DMEK.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
